玻璃体腔内注射雷珠单抗治疗老年黄斑变性的效果及安全性

目的探讨玻璃体腔内注射雷珠单抗治疗老年黄斑变性(AMD)的效果及安全性。方法回顾性分析本院2017年6月至2018年7月收治的68例(68眼)AMD患者的临床资料,按治疗方案的不同将患者分为参照组(34例,34眼,给予视网膜光凝治疗)和研究组(34例,34眼,给予玻璃体腔内注射雷珠单抗治疗)。比较两组治疗效果。结果治疗3个月后,两组患者平均眼压、CMT均明显降低,BCVA明显升高,且研究组优于参照组(P<0.05)。治疗1、3个月后,研究组患者CNV渗漏改善率显著高于参照组(P<0.05)。治疗3个月后,研究组患者眼底渗漏面积显著小于治疗前及参照组(P<0.05);两组患者并发症总发生率比较,差异无统计学意义(P>0.05)。结论玻璃体腔内注射雷珠单抗治疗AMD的效果显著,且安全性较高,值得临床推广。

Effect and safety of intravitreal injection of razumab in the treatment of aged macular degeneration

Objective To evaluate the effect and safety of intravitreal injection of razumab in the treatment of aged macular degeneration (AMD).Methods The clinical data of 68 patients (68 eyes) with AMD treated in our hospital from June 2017 to July 2018 were retrospectively analyzed.The patients were divided into reference group (34 cases, 34 eyes, treated with retinal photocoagulation) and research group (34 cases, 34 eyes, treated with intravitreal injection of razumab) according to different treatment schemes.The therapeutic effects of the two groups were compared.Results After 3 months of treatment, the average intraocular pressure and CMT of the two groups significantly decreased, and BCVA significantly increased, and those in the research group were better than the reference group (P<0.05).After 1, 3 months of treatment, the improvement rates of CNV leakage in the research group were significantly higher than those in the control group (P<0.05).After 3 months of treatment, the area of fundus leakage in the research group was significantly smaller than that before treatment and in the control group(P<0.05).There was no significant difference in the total incidence of complications between the two groups (P>0.05).Conclusion Intravitreal injection of razumab is effective and safe in the treatment of AMD, which is worthy of clinical promotion.